The company is still seeking strategic options for its development programs, including nana-val, which it was testing in EBV-positive refractory lymphoma.
The firm will make its artificial intelligence-based Lunit SCOPE IO platform available to SITC member researchers.
The Department of Health and Social Care is gauging whether AI technology can increase the number of patients screened by each radiologist.
Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback